Cargando…

A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors

FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid leukemia and a target for tyrosine kinase inhibitors (TKI). FLT3 TKIs have yielded limited improvements to clinical outcomes. One reason for this is TKI inhibition by endogenous factors. We characterized plasma pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Young, David J., Nguyen, Bao, Li, Li, Higashimoto, Tomoyasu, Levis, Mark J., Liu, Jun O., Small, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478262/ https://www.ncbi.nlm.nih.gov/pubmed/34589716 http://dx.doi.org/10.1158/2643-3230.BCD-20-0119

Ejemplares similares

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
por: Nguyen, Bao, et al.
Publicado: (2017)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
por: Zhu, Ruiqi, et al.
Publicado: (2021)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia
por: Jiang, Liling, et al.
Publicado: (2022)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2020)

Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells
por: Kang, Minyong, et al.
Publicado: (2017)

Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases
por: Zhu, Ying, et al.
Publicado: (2021)

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2021)

Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
por: Benes, Cyril H
Publicado: (2015)

Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
por: Krchniakova, Maria, et al.
Publicado: (2020)

PB1771: OVERCOMING RESISTANCE TO TYROSINE KINASE INHIBITORS IN MYELOID LEUKEMIA CELLS THROUGH ENHANCED FERROPTOSIS
por: Chien, Chih-Fang Chang, et al.
Publicado: (2023)

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
por: Song, Xiaoling, et al.
Publicado: (2021)

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
por: Allert, Catana, et al.
Publicado: (2022)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2020)

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
por: Katayama, Kazuhiro, et al.
Publicado: (2018)

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
por: Lei, Hu, et al.
Publicado: (2021)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
por: Nikolopoulos, Dionysis, et al.
Publicado: (2023)

Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Mumenthaler, Shannon M., et al.
Publicado: (2011)

Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein
por: Kawai, Hidetsugu, et al.
Publicado: (2019)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
por: Ryan, John J.
Publicado: (2016)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ
por: O’Sullivan, Susannah, et al.
Publicado: (2016)

Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors
por: Aveic, Sanja, et al.
Publicado: (2018)

FIKK Kinase, a Ser/Thr Kinase Important to Malaria Parasites, Is Inhibited by Tyrosine Kinase Inhibitors
por: Lin, Benjamin C., et al.
Publicado: (2017)

Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.
por: Gillespie, J., et al.
Publicado: (1993)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pqpqidnohiu38opc2r7vlomgus